R&D services will be provided by Chemical Diversity Research Institute, ChemDiv’s research subsidiary based in Moscow. The new agreement provides for research funding of clinical candidate compounds to POC.
Avineuro is responsible for further clinical development and commercialization of drug candidates AVN101, AVN211, and additional compounds that may be nominated for development from the ongoing research and discovery under the agreement.
ChemDiv has previously entered into an out-licensing and collaboration agreement with Avineuro to develop multiple compounds for Alzheimer disease and schizophrenia.